News & Events

Financial Results

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

31 January 2022

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

16 December 2021

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

6 December 2021

Inventiva reports 2021 Third Quarter Financial Information

10 November 2021

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

3 November 2021

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

27 October 2021

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis

21 September 2021

Inventiva reports 2021 first half financial results and provides a corporate update

20 September 2021

Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH

16 September 2021

Inventiva’s 2021 First-Half Financial Results Presentation

10 September 2021

Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH

8 September 2021

Inventiva announces the implementation of an At-The-Market program in the United States

Inventiva Reports First-Half of 2021 Financial Information

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event

Inventiva to participate at the Jefferies Virtual Healthcare Conference

Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit

Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors

Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting

Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

25 February 2021

Inventiva to participate at several investor conferences in March 2021

24 February 2021

Inventiva’s 2020 Full-Year Financial Results Presentation

23 February 2021

Full-Year 2020: Cash position and revenues

11 February 2021

Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

24 November 2020

Q3 2020 Financial Information

12 November 2020

Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference

9 November 2020

Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparcil

19 October 2020

Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH

12 October 2020

Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020

Inventiva to participate at several investor conferences in October 2020

24 September 2020

H1 2020 financial results and corporate business update

16 September 2020

Inventiva to participate at several investor conferences in September 2020

9 September 2020

Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range

Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing

H1 2020 Financial Information

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
ak_bmsc	2 hours	This cookie is used by Akamai to optimize site security by distinguishing between humans and bots
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
pll_language	1 year	The pll _language cookie is used by Polylang to remember the language selected by the user when returning to the website, and also to get the language information when not available in another way.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_173436417_1	1 Jour/s	Ces cookies sont utilisés pour collecter des informations sur la façon dont les visiteurs utilisent notre site Web. Ceci est unique au propriétaire du site Web
_gat_gtag_UA_55628332_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Cookie	Duration	Description
43410	session	No description available.
43411	session	No description
bm_mi	session	No description available.
DrupalVisitorMobile	session	No description available.
GZIP	5 years	No description available.

H1 2020 Financial Information